West Pharmaceutical Services, Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $1.51B (year ended Dec 31, 2016) to $3.07B (year ended Dec 31, 2025), a compound annual growth rate of 8.2%. The fastest growth was +31.9% in the year ended Dec 31, 2021; the weakest year was −1.9% (year ended Dec 31, 2024).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $3.07B | +6.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2026 |
| Dec 31, 2024 | $2.89B | −1.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2026 |
| Dec 31, 2023 | $2.95B | +2.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 17, 2026 |
| Dec 31, 2022 | $2.89B | +2.0% | Revenues | 10-K filed Feb 21, 2023 |
| Dec 31, 2021 | $2.83B | +31.9% | Revenues | 10-K filed Feb 21, 2023 |
| Dec 31, 2020 | $2.15B | +16.7% | Revenues | 10-K filed Feb 21, 2023 |
| Dec 31, 2019 | $1.84B | +7.1% | Revenues | 10-K filed Feb 22, 2022 |
| Dec 31, 2018 | $1.72B | +7.4% | Revenues | 10-K filed Feb 23, 2021 |
| Dec 31, 2017 | $1.60B | +6.0% | Revenues | 10-K filed Feb 24, 2020 |
| Dec 31, 2016 | $1.51B | +7.8% | Revenues | 10-K filed Feb 28, 2019 |
West Pharmaceutical Services, Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $874.50M | +8.7% | 10-Q filed Oct 29, 2026 |
| 3 months ended Jun 30, 2026 | $872.30M | +13.8% | 10-Q filed Jul 23, 2026 |
| 3 months ended Mar 31, 2026 | $844.90M | +21.0% | 10-Q filed Apr 23, 2026 |
| 3 months ended Sep 30, 2025 | $804.60M | +7.7% | 10-Q filed Oct 29, 2026 |
| 3 months ended Jun 30, 2025 | $766.50M | +9.2% | 10-Q filed Jul 23, 2026 |
| 3 months ended Mar 31, 2025 | $698.00M | +0.4% | 10-Q filed Apr 23, 2026 |
| 3 months ended Sep 30, 2024 | $746.90M | −0.1% | 10-Q filed Oct 23, 2025 |
| 3 months ended Jun 30, 2024 | $702.10M | −6.9% | 10-Q filed Jul 24, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 105770 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.